US Sleep-Wake Disorder Market Size to Reach $13.8 Billion by 2035

US sleep-wake disorder market is projected to grow from $7.6 billion in 2025 and is projected to reach $13.8 billion by 2035, growing at a CAGR of 6.2% during the forecast period 2026-2035. The US sleep-wake disorder market is being shaped by a rising prevalence of conditions linked to irregular sleep patterns, neurological imbalances, and lifestyle-related disruptions. Greater clinical attention toward early identification and structured management of sleep-related conditions has encouraged wider adoption of diagnostic pathways across healthcare settings. Hospitals and specialty clinics are increasingly incorporating advanced screening tools and digital monitoring systems to improve detection accuracy. At the same time, awareness among patients regarding long-term health implications of untreated sleep disturbances is supporting earlier consultation rates. The growing integration of behavioral health approaches with medical treatment is also influencing care delivery models. These combined factors are contributing to a more structured and proactive approach to sleep disorder management in the country.

Browse the full report description of “US Sleep-Wake Disorder Market Size, Share & Trends Analysis By Disorder Type (Insomnia, Hypersomnia, Sleep Apnea, Circadian Rhythm Sleep-Wake Disorders, Parasomnias, Dyssomnias, and Others), By Treatment Type (Pharmacological Therapy, Behavioral Therapy, Light Therapy, Device-Based Therapy, and Others), By Diagnosis & Management Approach (Polysomnography & Sleep Studies, Actigraphy-Based Monitoring, Clinical Evaluation & Screening Tools, and Remote/Digital Sleep Monitoring Solutions), and By Application (Hospitals, Home Care Settings, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/us-sleep-wake-disorder-market

Technological progress in diagnostic and therapeutic solutions is playing a central role in shaping market development in the United States. The adoption of home-based monitoring devices and remote care platforms is reducing dependence on traditional in-clinic evaluations while improving patient convenience. Pharmaceutical and medical device advancements are also expanding the range of available treatment options across different disorder types. Healthcare providers are increasingly focusing on personalized treatment strategies that combine pharmacological, behavioral, and device-based interventions. In addition, collaboration between technology firms and healthcare organizations is supporting the development of integrated care ecosystems. Evolving healthcare infrastructure and growing emphasis on digital health adoption are expected to continue influencing the direction of the market.

Competitive Landscape of the Sleep-Wake Disorder Market

The key players in the sleep-wake disorder market are ResMed Inc., Inspire Medical Systems Inc., Jazz Pharmaceuticals plc, Harmony Biosciences Holdings Inc., and Eli Lilly and Company, among others. The competitive landscape is characterized by companies focusing on differentiated approaches across diagnosis, pharmacological treatment, and device-based therapies for sleep-related conditions. Strong emphasis is placed on expanding therapeutic options for disorders such as insomnia and obstructive sleep apnea through both medical and technological advancements. Market participants are increasingly investing in non-invasive treatment modalities and digital health integration to improve patient adherence and monitoring outcomes. Continuous research activity and product refinement efforts are also contributing to broader clinical adoption across healthcare systems.

• In March 2026, LivaNova secured US FDA Premarket Approval (PMA) for its Aura6000 system, an advanced hypoglossal nerve stimulation therapy for moderate to severe obstructive sleep apnea. The system represents a new-generation implantable neurostimulation approach for patients intolerant to CPAP therapy. The approval expands US treatment options beyond traditional airflow-based therapies toward neuromodulation-based interventions.

• In April 2025, ResMed expanded its US sleep portfolio through the launch of Smart Comfort, an AI-enabled CPAP personalization technology, designed to improve adherence through machine-learning-driven therapy adjustments. Additionally, its NightOwl home sleep apnea test became widely available across the United States, strengthening decentralized sleep disorder diagnosis.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Disorder Type
  • By Treatment Type
  • By Diagnosis & Management Approach
  • By Application
• Competitive Landscape - ResMed Inc., Inspire Medical Systems Inc., Jazz Pharmaceuticals plc, Harmony Biosciences Holdings Inc., and Eli Lilly and Company.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

US Sleep-Wake Disorder Market Report Segment

By Disorder Type

• Insomnia
• Hypersomnia
• Sleep Apnea
• Circadian Rhythm Sleep-Wake Disorders
• Parasomnias
• Dyssomnias
• Others

By Treatment Type

• Pharmacological Therapy
• Behavioral Therapy
• Light Therapy
• Device-Based Therapy
• Others

By Diagnosis & Management Approach

• Polysomnography & Sleep Studies
• Actigraphy-Based Monitoring
• Clinical Evaluation & Screening Tools
• Remote / Digital Sleep Monitoring Solutions

By Application

• Hospitals
• Home Care Settings
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-sleep-wake-disorder-market